ZNTL
Zentalis Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
1.96
close · 2026-10-30
value
7
cheaper than peers7
quality
31
stronger fundamentals31
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.98× | 80 |
| earnings yield, latest year | -97.4% | 21 |
| cash flow yield, latest year | -65.1% | 19 |
| earnings yield, 3 years ago | -228.6% | 19 |
| earnings yield, 1 year ago | -118.9% | 19 |
| earnings yield, 2 years ago | -228.1% | 15 |
| cash flow yield, 1 year ago | -89.0% | 15 |
| cash flow yield, 3 years ago | -86.5% | 14 |
| cash flow yield, 2 years ago | -108.4% | 11 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -66.7% | 50 |
| operating margin | 0.0% | 50 |
| debt to equity | 26.2% | 23 |
3 of 4 measures available
Facts
| market cap | $192M |
| free cash flow | -$79.5M |
| employees | 106 |
| first trade | 2020-04-03 |
| next earnings | not reported |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.91 | -2.33 | -4.47 | -4.48 |
| free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M |
| net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M |
| revenue | $0 | $67.4M | $0 | $0 |
| unusual items | $8.4M | $21.8M | -$23.0M | $6.0M |